Free Trial
NASDAQ:CRBU

Caribou Biosciences (CRBU) Stock Price, News & Analysis

Caribou Biosciences logo
$1.80 -0.01 (-0.55%)
(As of 12/20/2024 05:51 PM ET)

About Caribou Biosciences Stock (NASDAQ:CRBU)

Key Stats

Today's Range
$1.76
$1.86
50-Day Range
$1.77
$2.79
52-Week Range
$1.50
$8.33
Volume
1.99 million shs
Average Volume
1.70 million shs
Market Capitalization
$163.00 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.20
Consensus Rating
Buy

Company Overview

Caribou Biosciences, Inc. is a cutting-edge biopharmaceutical company headquartered in Berkeley, California. Founded in 2011 by Dr. Rachel E. Haurwitz and other prominent scientists, the company is a leader in the field of genome-editing therapies. Caribou utilizes CRISPR-Cas technology to develop precision cell therapies for patients suffering from hematologic malignancies and solid tumors. The company's vision is to revolutionize the treatment landscape for devastating diseases by providing innovative and personalized therapies.

Caribou Biosciences' journey began as a spinoff from research conducted at the University of California, Berkeley, where Dr. Haurwitz and her colleagues worked on harnessing the CRISPR-Cas system for advanced gene-editing applications. Leveraging their expertise, the team established Caribou to explore the potential of genome editing in developing transformative therapeutics.

The company is committed to pushing the boundaries of science and medicine, focusing on creating precision cell therapies that target specific genetic mutations in patients' cells. By modifying these cells, Caribou aims to enhance antitumor activity and provide tailored treatments to address the unique genetic characteristics of each patient's disease.

Caribou Biosciences operates in the biological products industry, specializing in genome-editing therapies. The company's dedication to research and innovation has positioned it as a key player in the field, with significant potential to impact the future of medical treatments.

The company's mission statement revolves around the core belief in the power of genome-editing technology to unlock new possibilities for disease treatment and patient care. Caribou is committed to advancing its pipeline of precision cell therapies and translating cutting-edge science into transformative solutions for patients worldwide.

The leadership team at Caribou Biosciences comprises accomplished professionals with extensive expertise in the biopharmaceutical and scientific domains. Dr. Rachel E. Haurwitz, who co-founded the company and serves as the Chief Executive Officer, President, and Director. With a Ph.D. in Molecular and Cell Biology from UC Berkeley, Dr. Haurwitz was pivotal in developing CRISPR-based gene-editing technologies. Assisting Dr. Haurwitz is Ms. Ruhi A. Khan, the Chief Business Officer responsible for driving strategic partnerships and business development initiatives. Ms. Khan brings a wealth of experience in the biopharmaceutical industry and has been instrumental in shaping Caribou's collaborations. Dr. Syed Ali-aamir Rizvi serves as the Chief Medical Officer, contributing his expertise in clinical development and medical affairs. With a strong background in hematology and oncology, Dr. Rizvi is critical in guiding the clinical progress of Caribou's precision cell therapies. The management team's collective experience, dedication to innovation, and scientific prowess have propelled Caribou Biosciences to the forefront of the genome-editing industry.

Caribou Biosciences has demonstrated steady revenue growth over the past few years. However, the company is operating at a loss, with a net negative income of close to $100 million. The negative net profit margins result from substantial operating expenses associated with advancing the pipeline of precision cell therapies. Caribou Biosciences' innovative approach to precision cell therapies and its pioneering work in genome editing have garnered investor interest and positive sentiment, contributing to the stock's potential upside.

The stock performance of Caribou Biosciences is subject to various factors, including market conditions, investor sentiment, and news related to the company's progress. Investors closely monitor the company's milestones, clinical trial results, and partnership agreements, which can significantly impact the stock price.

Caribou Biosciences operates in the highly competitive field of biopharmaceuticals, focusing on genome-editing therapies. The broader industry has witnessed significant advancements in CRISPR technology, with various companies vying to develop precision cell therapies. Caribou's competitive advantage lies in its patented Cas12a chRDNA technology, which enables superior precision in genome editing and the development of armored cell therapies.

The company's pipeline of precision cell therapies presents promising growth opportunities. With its CAR-T and CAR-NK platforms targeting hematologic malignancies and solid tumors, Caribou aims to cater to patients with critical medical needs. The company's dedication to scientific excellence and pioneering research positions it well to capitalize on the potential of genome-editing therapies.

Caribou Biosciences faces several potential risks and challenges common to clinical-stage biopharmaceutical companies. These include uncertainties in clinical trials, regulatory approval processes, and market competition. However, Caribou's risk management strategies and scientific expertise serve as potential mitigating factors.

Caribou Biosciences Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
44th Percentile Overall Score

CRBU MarketRank™: 

Caribou Biosciences scored higher than 44% of companies evaluated by MarketBeat, and ranked 637th out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Caribou Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Caribou Biosciences has only been the subject of 2 research reports in the past 90 days.

  • Read more about Caribou Biosciences' stock forecast and price target.
  • Earnings Growth

    Earnings for Caribou Biosciences are expected to decrease in the coming year, from ($1.64) to ($1.84) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Caribou Biosciences is -1.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Caribou Biosciences is -1.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Caribou Biosciences has a P/B Ratio of 0.43. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    10.89% of the float of Caribou Biosciences has been sold short.
  • Short Interest Ratio / Days to Cover

    Caribou Biosciences has a short interest ratio ("days to cover") of 6.7.
  • Change versus previous month

    Short interest in Caribou Biosciences has recently increased by 16.17%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Caribou Biosciences does not currently pay a dividend.

  • Dividend Growth

    Caribou Biosciences does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    10.89% of the float of Caribou Biosciences has been sold short.
  • Short Interest Ratio / Days to Cover

    Caribou Biosciences has a short interest ratio ("days to cover") of 6.7.
  • Change versus previous month

    Short interest in Caribou Biosciences has recently increased by 16.17%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Caribou Biosciences has a news sentiment score of 1.48. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.60 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Caribou Biosciences this week, compared to 2 articles on an average week.
  • Search Interest

    Only 6 people have searched for CRBU on MarketBeat in the last 30 days. This is a decrease of -45% compared to the previous 30 days.
  • MarketBeat Follows

    1 people have added Caribou Biosciences to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Caribou Biosciences insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 9.50% of the stock of Caribou Biosciences is held by insiders.

  • Percentage Held by Institutions

    77.51% of the stock of Caribou Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Caribou Biosciences' insider trading history.
Receive CRBU Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Caribou Biosciences and its competitors with MarketBeat's FREE daily newsletter.

CRBU Stock News Headlines

Caribou Biosciences Reports Q3 2024 Financial Results
Your bank is lying to you.
You might think you have your money in a high-yield savings account, but do you really? The national average APY on savings is just 0.58%, but you can get up to 5.0% APY online with these accounts.
Evercore ISI Remains a Hold on Caribou Biosciences (CRBU)
See More Headlines

CRBU Stock Analysis - Frequently Asked Questions

Caribou Biosciences' stock was trading at $5.73 at the beginning of the year. Since then, CRBU stock has decreased by 68.6% and is now trading at $1.80.
View the best growth stocks for 2024 here
.

Caribou Biosciences, Inc. (NASDAQ:CRBU) announced its quarterly earnings data on Wednesday, November, 6th. The company reported ($0.38) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.44) by $0.06. The firm earned $2.02 million during the quarter, compared to analysts' expectations of $3.37 million. Caribou Biosciences had a negative net margin of 1,290.81% and a negative trailing twelve-month return on equity of 45.46%.

Caribou Biosciences (CRBU) raised $202 million in an IPO on Friday, July 23rd 2021. The company issued 13,500,000 shares at a price of $14.00-$16.00 per share.

Top institutional shareholders of Caribou Biosciences include PFM Health Sciences LP (4.76%), Elmwood Wealth Management Inc. (2.41%), Geode Capital Management LLC (2.24%) and FMR LLC (1.75%). Insiders that own company stock include Steven Kanner, Ryan Fischesser and Syed Ali-Aamir Rizvi.
View institutional ownership trends
.

Shares of CRBU stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Caribou Biosciences investors own include Voyager Therapeutics (VYGR), American Water Works (AWK), The RMR Group (RMR), Waste Connections (WCN), AUO (AUOTY), DiamondRock Hospitality (DRH) and iShares Micro-Cap ETF (IWC).

Company Calendar

Last Earnings
11/06/2024
Today
12/22/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:CRBU
Fax
N/A
Employees
100
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$10.20
High Stock Price Target
$19.00
Low Stock Price Target
$3.00
Potential Upside/Downside
+466.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-102,070,000.00
Net Margins
-1,290.81%
Pretax Margin
-1,289.12%

Debt

Sales & Book Value

Annual Sales
$11.48 million
Book Value
$4.17 per share

Miscellaneous

Free Float
81,950,000
Market Cap
$163.00 million
Optionable
Optionable
Beta
2.27
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

This page (NASDAQ:CRBU) was last updated on 12/22/2024 by MarketBeat.com Staff
From Our Partners